We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Evgen Pharma plc (EVG) Ordinary 0.25p

Sell:3.40p Buy:3.50p 0 Change: No change
Market closed Prices as at close on 30 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.40p
Buy:3.50p
Change: No change
Market closed Prices as at close on 30 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:3.40p
Buy:3.50p
Change: No change
Market closed Prices as at close on 30 June 2022 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Evgen Pharma plc is a clinical stage drug development company. The Company is developing sulforaphane-based medicines focused on the treatment of cancer and inflammation. The Company's pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01 for the treatment of metastatic breast cancer and acute respiratory distress syndrome. The SFX-01 reduces the number of cancer stem cells in patient-derived breast cancer tissue in xenograft models. Its SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin.

Contact details

Address:
The Colony
146 Brownlow Hill, Altrincham Road
WILMSLOW
SK9 4LY
United Kingdom
Telephone:
+44 (0151) 7053532
Website:
evgen.com/

Important dates

Future events
There are no future events available.
Past events
Final results 08 June 2022 08/06/22
Interim results 07 December 2021 07/12/21
AGM 13 July 2021 13/07/21

General stock information

EPIC:
EVG
ISIN:
GB00BSVYN304
Market cap:
£9.48 million
Shares in issue:
274.89 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Huw Jones
    Chief Executive Officer, Executive Director
  • Richard Moulson
    Chief Financial Officer, Executive Director
  • Glen Clack
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.